NicOx confirms its strategy in ophthalmology
NicOx stock market soared Wednesday after announcing the signing of an agreement to acquire 11.8% stake in Altacor, a UK ophthalmology which the group can be subsequently 100% control.
The action of the French biotech company closed at 4.22 euros (35.43%) in a volume of 28.4 million shares, more than 12.5 times higher than recorded daily average last three months. Its market capitalization stood at 307 million euros.
She had also made great progress there is a little over a week after announcing positive results of a study on treatment of glaucoma developed with the specialist eye health Bausch + Lomb.
Under the terms of the agreement, NicOx will invest an amount of two million pounds (about 2.4 million euros) in cash to acquire 11.8% of Altacor, which markets a product line the UK for the problems of dry eye.
The group has an option to acquire the remaining shares Altacor for $ 9 million pounds (about 10.8 million), paid , at the option of NicOx, in cash or in shares NicOx in a combination of cash and shares.
This option is exercisable by NicOx until May 31, 2012. If predefined steps are met, additional payments of up to a total of 8.5 million pounds will be due.
ACTION HIGH RISK
The option to acquire concludes Altacor, is the first concrete realization of the strategy initiated over a year by NicOx to refocus around ophthalmology Aftern ; s failure of anti-inflammatory Naproxcinod, Malafosse says Sebastian, an analyst at Bryan Garnier.
The intermediary considers that the offer of the biotech values between 13.2 and 23.4 million Altacor society, which has an annual turnover of 660,000 euros.
Another analyst, who requested anonymity, considers "very speculative ascent of a security that has increased from 12 euros in the second half of 2006 to 22 euros at the highest early 2007 before falling between 1 and 2 since the failure of Naproxcinod ".
He also observed that in the preferred areas of Altacor, including dry eye, NicOx "mastodons" in front of him such as Novartis, Merck and Sanofi.
"NicOx announces investment potential of 26 million euros for a target with confidential sales and capitalization is around 80 million euros. Michele Garufi, CEO of NicOx is too strong or some investors revved up a rather quickly, "said he.